Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Plus Therapeutics ( (PSTV) ) has provided an announcement.
On March 11, 2026, Plus Therapeutics’ board set the company’s 2026 Annual Meeting of Stockholders for Thursday, May 14, 2026, at 9:00 a.m. Eastern Time, to be held virtually by remote communication, with stockholders of record as of the close of business on March 18, 2026 entitled to notice and voting rights, though the company reserved the right to change the meeting details and record date. Because the 2026 Annual Meeting falls more than 30 days before the anniversary of the 2025 meeting, Plus Therapeutics reset the deadlines for shareholder proposals and director nominations, requiring Rule 14a-8 proposals, bylaw-based business, and any universal proxy-related director nomination notices to be received by the corporate secretary no later than 5:00 p.m. Eastern Time on March 22, 2026, reinforcing the procedural framework for shareholder participation and governance ahead of the meeting.
The most recent analyst rating on (PSTV) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Underperform.
The score is driven primarily by weak financial performance—large ongoing losses, sharply negative free cash flow, and continued funding risk despite low debt. Technicals also weigh on the score with a clear downtrend (price below key moving averages and negative MACD), only partially offset by oversold readings. Valuation support is limited because the company is loss-making (negative P/E) and no dividend yield is provided.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Plus Therapeutics, Inc. is a U.S.-based healthcare company operating in the biopharmaceutical sector, with its common stock held by a broad base of public stockholders. The company is governed by a board of directors and follows standard U.S. securities and corporate governance rules, including SEC proxy regulations and Delaware corporate law in managing its shareholder meetings and director elections.
Average Trading Volume: 9,636,924
Technical Sentiment Signal: Sell
Current Market Cap: $54.88M
See more insights into PSTV stock on TipRanks’ Stock Analysis page.